Shares of Eli Lilly LLY moved lower by 2.3% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share rose 26.00% year over year to $1.89, which beat the estimate of $1.56.
Revenue of $5,499,000,000 declined by 2.45% year over year, which missed the estimate of $5,760,000,000.
Looking Ahead
The upcoming fiscal year's EPS expected to be between $7.20 and $7.40.
The upcoming fiscal year's revenue expected to be between $23,700,000,000 and $24,200,000,000.
How To Listen To The Conference Call
Date: Jul 30, 2020
Time: 09:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/9cyavje9
Recent Stock Performance
Company's 52-week high was at $170.75
Company's 52-week low was at $101.36
Price action over last quarter: down 0.19%
Company Description
Eli Lilly is a drug company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
